Xeljanz® use for RA on the rise (but so is its discontinuation rate)

Nearly half of Xeljanz® users discontinue the costly RA drug after one year

February 9, 2017

Prime research shows nearly half of Xeljanz® users discontinue the costly rheumatoid arthritis (RA) drug after one year

The FDA approved Tofacitinib (Xeljanz®) for people with RA who have an inadequate response to methotrexate. The study found that one in 10 members were potentially not following guidelines to use tofacitininb as second line therapy. Additionally, 44 percent of members discontinued the drug by one year. RA is a chronic condition that needs ongoing treatment; this study show there is opportunity for improvement. Plan sponsors should develop care and utilization management programs that encourage adherence and cost-effective treatment strategies.

Tofacitinib (Xeljanz®) Utilization Patterns and Persistency Among 4.4 Million Continuously Enrolled Commercially Insured Members Over Four Years (Fall 2016)

Related news

Perspectives

August 15, 2022

September 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Perspectives

August 4, 2022

Specialty Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

August 4, 2022

Traditional Drug Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…